NVO/N Stock Price and Chart — BMV:NVO/N

Overview

Financials News Ideas Discussions Technicals Forecast Seasonals Bonds

NVO/N chart

Key facts today

Novo Nordisk partnered with Hims & Hers to offer Wegovy via the Hims platform for $599 monthly. This news boosted Novo Nordisk's shares by 3.4%.

LifeMD plans to provide broad access to Novo Nordisk's weight-loss drug Wegovy, offering all doses in a pen device for eligible patients who are uninsured or lack coverage for weight-loss medications.

Analyze the impact Analyze the impact

NVO/N upcoming earnings

Key stats

About NOVO NORDISK B A/S

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.